Biotech Showcase 2015 EBD Group Demy-Colton Image Map
Share:
Email this page Share this on LinkedIn Share this on Twitter | print this page

Biotech Showcase™ 2015 Program Overview

www.ebdgroup.com/bts/program
Sunday, January 11, 2015
1:00–5:00 pm
BioMentorz Workshop
The tactics of closing funding deals

This workshop is focused on delivering results and securing funding at All Levels: Boards, Angels, VCs, Corporate Partners and Other Sources of Funds, with four hours of intensive and interactive discussion, on-your-feet sessions, war stories and insights aimed at folks looking for financing. It is designed to accelerate your funding activities and eliminate unnecessary noise.

Preregistration is required, more information can be found here.

4:00–7:00 pm
Level 4, Cyril Magnin Foyer

All Biotech Showcase attendees are invited to pick up name badges prior to the beginning of the conference on Monday.

Monday, January 12, 2015
7:00 am
Level 4, Cyril Magnin Foyer
Registration Opens and Continental Breakfast
8:00–9:00 am
Workshop
Reading the tea leaves: How to interpret FDA, CMS, and SEC actions

What do actions and non-actions from the FDA, CMS, and SEC mean for biotech companies advancing products in development and investors in these companies? What events are par for the course, and what constitutes a red flag? How do you know whether a company has a good chance of succeeding? Or, will it fall prey to the ever-increasing bureaucracies? The session will include experts in working with the FDA and CMS.

Share this:Email this pageShare this on LinkedInShare this on Twitter
8:00–9:50 am
Alliance for Regenerative Medicine
State of the Industry Briefing

Share this:Email this pageShare this on LinkedInShare this on Twitter
8:00 am–12:00 pm Company Presentations ►

Private Biotech
Public Biotech

12:00–1:30 pm
Lunch Plenary
Value creation: Private and Public investment strategies and stage gates for success

How do investors perceive value? Each stakeholder will place a different value on assets in each phase for different reasons; each type of investor will assess value with their own, unique focus. There is no longer one set of rules to evaluate pharma/biotech investments.

Evolving market dynamics dictate a shift in focus toward products where innovation still drives market value. In addition, development times differ by therapeutic area, as do product types, new indication and treatment paradigms—all of which change over time. The value defined today may not be the value realized in the future. Therefore, investment strategy must converge with existing company strategic strengths in established and existing areas of corporate investment. Whether a public or private investment, value will drive the deal.

Join this panel of senior industry executives from emerging biotechs, large pharmas, VC firms and investment banks as they discuss the key drivers that dictate "value" creation, and which pitfalls to avoid on the path to acquisition, partnership or joint commercialization models.

Moderator:
Mike Griffith – Executive VP Commercial Division, inVentiv Health

Panelists:
  • Stephen Bloch – General Partner, Canaan Partners
  • Ross Hammerman – Managing Director, UBS Investment Bank
  • John V. Oyler – Founder and CEO, BeiGene
  • Melinda Richter – Head of Johnson & Johnson Innovation, JLabs
Share this:Email this pageShare this on LinkedInShare this on Twitter
1:45–5:30 pm Company Presentations ►

Private Biotech
Public Biotech

1:30–6:00 pm
One-to-one Meetings ►
Tuesday, January 13, 2015
7:00 am
Level 4, Cyril Magnin Foyer
Registration Opens and Continental Breakfast
8:00–9:00 am
Workshops
Type 1 Diabetes: Novel therapies, devices and diagnostics on the horizon

As a chronic and highly prevalent (>1 million patients in US) autoimmune disease, type 1 diabetes (T1D), especially if inadequately treated, has a major impact on the healthcare system and dramatically affects patient quality of life. This session will highlight some of the innovative therapies and devices in development to better treat (and cure and prevent), reduce complications and relieve the daily burden of T1D. Furthermore, the panelists will discuss the commercial opportunities for companies developing innovative and impactful disease-modifying agents for this chronic disease and why this makes T1D-focused companies an attractive investment option.

Moderator:
Richard Insel – Chief Scientific Officer, JDRF

Panelists:
  • Richard Berenson – CEO, Thermalin Diabetes, LLC
  • Werner Cautreels – President and CEO, Selecta Biosciences
  • Paul Laikind – President and CEO, ViaCyte, Inc
  • Howard Look – President and CEO, Tidepool
Share this:Email this pageShare this on LinkedInShare this on Twitter
Streetwise Reports 2015 Watch List

Share this:Email this pageShare this on LinkedInShare this on Twitter
Financing biotech more—or less—by the book

New forms of financing such as crowdfunding are trying to establish a toehold in life sciences. How can the different approaches coexist? What sort of biotechs will arise in a universe populated with these investors? How will existing players adapt?

Share this:Email this pageShare this on LinkedInShare this on Twitter
8:00 am–12:00 pm
One-to-one Meetings ►
8:00 am–12:00 pm Company Presentations ►

Private Biotech
Public Biotech

12:00–1:30 pm
Lunch Plenary
How robust is the biotech rally and what could derail it?

The biotech rally has fueled a steady stream of IPOs over the last two years, and there is optimism that this time the market is driven to results rather than hype. Commercialization may have brought some stability and sustainability to the market for biopharmaceutical companies, but there are still significant issues that could derail investment even in profitable firms. Backlash over drug pricing and compassionate use could cause generalist investors to balk. Public policy set-backs could undo many of the gains the industry has made under the JOBS Act. A less cooperative FDA slows key approvals and thus slows the momentum of the industry. Our panel will explore these issues and others that are key to the sector's financial sustainability.

Share this:Email this pageShare this on LinkedInShare this on Twitter
1:45–5:30 pm Company Presentations ►

Private Biotech
Public Biotech

1:30–6:00 pm
One-to-one Meetings ►
Wednesday, January 14, 2015
7:00 am
Level 4, Cyril Magnin Foyer
Registration Opens and Continental Breakfast
8:00–9:00 am
Workshop
Apps as drug

Startups are pushing forward in several disease areas to augment or supplant pharmaceutical approaches with online apps or computer programs. In focus are areas like migraine, sleep and diabetes because those are both closely linked to regulated areas (insomnia drugs, insulin). The focus will be less on those apps that cover areas already addressed by pharmaceuticals, not "lifestyle" apps.

Share this:Email this pageShare this on LinkedInShare this on Twitter
8:00 am–12:00 pm
One-to-one Meetings ►
8:00 am–12:00 pm Company Presentations ►

Private Biotech
Public Biotech

12:00–1:30 pm
Lunch Plenary
Flush with funds: What are VCs looking for?

A healthy market for exits, both IPOs and M&A, has replenished the coffers of life sciences VCs as well as improved the fundraising environment. At least half a dozen new funds have been announced in recent months. At the same time, corporate venture investment in life sciences is at a five-year high.

How will all of this fresh capital be deployed? As long as the IPO window is open, crossover rounds will continue to account for a large percentage of investment capital. But will VCs also turn their attention to early stage opportunities in a quest to unlock innovative new technologies? And how will unconventional investments such as big pharma partnering directly with academic researchers, crowdfunding or accelerators and incubators impact the private investment ecosystem?

Share this:Email this pageShare this on LinkedInShare this on Twitter
1:45–5:00 pm Company Presentations ►

Private Biotech
Public Biotech

1:30–5:00 pm
One-to-one Meetings ►
5:00–6:00 pm
Level 4, Cyril Magnin Foyer
Closing Reception
Arrow Up


© 2009–2014 EBD Group, Inc.
Biotech Showcase 2015 EBD Group Demy-Colton Image Map